APRE
Aprea Therapeutics Inc (APRE)
Healthcare • NASDAQ • $0.66+3.67%
- Symbol
- APRE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.66
- Daily Change
- +3.67%
- Market Cap
- $8.42M
- Trailing P/E
- N/A
- Forward P/E
- -1.28
- 52W High
- $1.75
- 52W Low
- $0.55
- Analyst Target
- $3.55
- Dividend Yield
- N/A
- Beta
- N/A
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Company websiteResearch APRE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.